APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncology Treatment Drug Market Outlook and Growth Opportunities 2026

2 January 2026215 pages

Choose your research edition.

Industry ResearchOncology Treatment Drug Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Treatment Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Oncology Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Treatment Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Treatment Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Oncology Treatment Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncology Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncology Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncology Treatment Drug market include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Merck KGaA, Roche and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oncology Treatment Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Treatment Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Treatment Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oncology Treatment Drug market.

Oncology Treatment Drug Segment by Company

Takeda

Eisai

Teva

Sanofi

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

Bayer

Amgen

AbbVie

AstraZeneca

Otsuka

Merck & Co.

Ipsen

Gilead Sciences

Celgene

Bristol-Myers Squibb

Biogen Idec

Astellas

Oncology Treatment Drug Segment by Type

Immunotherapy (Biologic Therapy)

Chemotherapy

Hormonal Therapy

Targeted Therapy

Others

Oncology Treatment Drug Segment by Application

Respiratory/Lung Cancer

Prostate Cancer

Breast Cancer

Gastrointestinal Cancer

Blood Cancer

Others

Oncology Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Oncology Treatment Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oncology Treatment Drug key companies, revenue, market share, and recent developments.

3. To split the Oncology Treatment Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oncology Treatment Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology Treatment Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology Treatment Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Treatment Drug industry.

Chapter 3: Detailed analysis of Oncology Treatment Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oncology Treatment Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oncology Treatment Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology Treatment Drug Industry Trends Table 2. Oncology Treatment Drug Industry Drivers Table 3. Oncology Treatment Drug Industry Opportunities and Challenges Table 4. Oncology Treatment Drug Industry Restraints Table 5. Global Oncology Treatment Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology Treatment Drug Revenue Share by Company (2021-2026) Table 7. Global Oncology Treatment Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oncology Treatment Drug Key Company Manufacturing Base & Headquarters Table 9. Global Oncology Treatment Drug Company, Product Type & Application Table 10. Global Oncology Treatment Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oncology Treatment Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Immunotherapy (Biologic Therapy) Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Hormonal Therapy Table 17. Significant Companies of Targeted Therapy Table 18. Significant Companies of Others Table 19. Global Oncology Treatment Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Oncology Treatment Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Oncology Treatment Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Oncology Treatment Drug Sales Value Share by Type (2021-2026) Table 23. Global Oncology Treatment Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Respiratory/Lung Cancer Table 25. Significant Companies of Prostate Cancer Table 26. Significant Companies of Breast Cancer Table 27. Significant Companies of Gastrointestinal Cancer Table 28. Significant Companies of Blood Cancer Table 29. Significant Companies of Others Table 30. Global Oncology Treatment Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oncology Treatment Drug Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Oncology Treatment Drug Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Oncology Treatment Drug Sales Value Share by Application (2021-2026) Table 34. Global Oncology Treatment Drug Sales Value Share by Application (2027-2032) Table 35. Global Oncology Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Oncology Treatment Drug Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Oncology Treatment Drug Sales Value Share by Region (2021-2026) Table 38. Global Oncology Treatment Drug Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Oncology Treatment Drug Sales Value Share by Region (2027-2032) Table 40. Global Oncology Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Oncology Treatment Drug Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Oncology Treatment Drug Sales Value Market Share by Country (2021-2026) Table 43. Global Oncology Treatment Drug Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Oncology Treatment Drug Sales Value Market Share by Country (2027-2032) Table 45. Takeda Company Information Table 46. Takeda Business Overview Table 47. Takeda Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Takeda Oncology Treatment Drug Product Portfolio Table 49. Takeda Recent Development Table 50. Eisai Company Information Table 51. Eisai Business Overview Table 52. Eisai Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Eisai Oncology Treatment Drug Product Portfolio Table 54. Eisai Recent Development Table 55. Teva Company Information Table 56. Teva Business Overview Table 57. Teva Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Teva Oncology Treatment Drug Product Portfolio Table 59. Teva Recent Development Table 60. Sanofi Company Information Table 61. Sanofi Business Overview Table 62. Sanofi Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Sanofi Oncology Treatment Drug Product Portfolio Table 64. Sanofi Recent Development Table 65. Johnson & Johnson Company Information Table 66. Johnson & Johnson Business Overview Table 67. Johnson & Johnson Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Johnson & Johnson Oncology Treatment Drug Product Portfolio Table 69. Johnson & Johnson Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novartis Oncology Treatment Drug Product Portfolio Table 74. Novartis Recent Development Table 75. Merck KGaA Company Information Table 76. Merck KGaA Business Overview Table 77. Merck KGaA Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck KGaA Oncology Treatment Drug Product Portfolio Table 79. Merck KGaA Recent Development Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Roche Oncology Treatment Drug Product Portfolio Table 84. Roche Recent Development Table 85. Eli Lilly Company Information Table 86. Eli Lilly Business Overview Table 87. Eli Lilly Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Eli Lilly Oncology Treatment Drug Product Portfolio Table 89. Eli Lilly Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Oncology Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Oncology Treatment Drug Product Portfolio Table 94. Pfizer Recent Development Table 95. Bayer Company Information Table 96. Bayer Business Overview Table 97. Bayer Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bayer Oncology Treatment Drug Product Portfolio Table 99. Bayer Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Amgen Oncology Treatment Drug Product Portfolio Table 104. Amgen Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. AbbVie Oncology Treatment Drug Product Portfolio Table 109. AbbVie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. AstraZeneca Oncology Treatment Drug Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Otsuka Company Information Table 116. Otsuka Business Overview Table 117. Otsuka Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Otsuka Oncology Treatment Drug Product Portfolio Table 119. Otsuka Recent Development Table 120. Merck & Co. Company Information Table 121. Merck & Co. Business Overview Table 122. Merck & Co. Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Merck & Co. Oncology Treatment Drug Product Portfolio Table 124. Merck & Co. Recent Development Table 125. Ipsen Company Information Table 126. Ipsen Business Overview Table 127. Ipsen Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Ipsen Oncology Treatment Drug Product Portfolio Table 129. Ipsen Recent Development Table 130. Gilead Sciences Company Information Table 131. Gilead Sciences Business Overview Table 132. Gilead Sciences Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Gilead Sciences Oncology Treatment Drug Product Portfolio Table 134. Gilead Sciences Recent Development Table 135. Celgene Company Information Table 136. Celgene Business Overview Table 137. Celgene Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Celgene Oncology Treatment Drug Product Portfolio Table 139. Celgene Recent Development Table 140. Bristol-Myers Squibb Company Information Table 141. Bristol-Myers Squibb Business Overview Table 142. Bristol-Myers Squibb Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Bristol-Myers Squibb Oncology Treatment Drug Product Portfolio Table 144. Bristol-Myers Squibb Recent Development Table 145. Biogen Idec Company Information Table 146. Biogen Idec Business Overview Table 147. Biogen Idec Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Biogen Idec Oncology Treatment Drug Product Portfolio Table 149. Biogen Idec Recent Development Table 150. Astellas Company Information Table 151. Astellas Business Overview Table 152. Astellas Oncology Treatment Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Astellas Oncology Treatment Drug Product Portfolio Table 154. Astellas Recent Development Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Oncology Treatment Drug Product Image Figure 2. Global Oncology Treatment Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Treatment Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncology Treatment Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Immunotherapy (Biologic Therapy) Image Figure 8. Chemotherapy Image Figure 9. Hormonal Therapy Image Figure 10. Targeted Therapy Image Figure 11. Others Image Figure 12. Global Oncology Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Oncology Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Oncology Treatment Drug Sales Value Share by Type (2021-2032) Figure 15. Respiratory/Lung Cancer Image Figure 16. Prostate Cancer Image Figure 17. Breast Cancer Image Figure 18. Gastrointestinal Cancer Image Figure 19. Blood Cancer Image Figure 20. Others Image Figure 21. Global Oncology Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oncology Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Oncology Treatment Drug Sales Value Share by Application (2021-2032) Figure 24. Global Oncology Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Oncology Treatment Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Oncology Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 27. North America Oncology Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Oncology Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Oncology Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Oncology Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Oncology Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Oncology Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 33. South America Oncology Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Oncology Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Oncology Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Oncology Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy
  • Others
Applications
  • Respiratory/Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Blood Cancer
  • Others
Companies covered
  • Takeda
  • Eisai
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Otsuka
  • Merck & Co.
  • Ipsen
  • Gilead Sciences
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncology Treatment Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncology Treatment Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oncology Treatment Drug Market Dynamics
  1. 2.1 Oncology Treatment Drug Industry Trends
  2. 2.2 Oncology Treatment Drug Industry Drivers
  3. 2.3 Oncology Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Treatment Drug Industry Restraints
3 Oncology Treatment Drug Market by Company
  1. 3.1 Global Oncology Treatment Drug Company Revenue Ranking in 2025
  2. 3.2 Global Oncology Treatment Drug Revenue by Company (2021-2026)
  3. 3.3 Global Oncology Treatment Drug Company Ranking (2024-2026)
  4. 3.4 Global Oncology Treatment Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Oncology Treatment Drug Company Product Type and Application
  6. 3.6 Global Oncology Treatment Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oncology Treatment Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oncology Treatment Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oncology Treatment Drug Market by Type
  1. 4.1 Oncology Treatment Drug Type Introduction
  2. 4.1.1 Immunotherapy (Biologic Therapy)
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Hormonal Therapy
  5. 4.1.4 Targeted Therapy
  6. 4.1.5 Others
  7. 4.2 Global Oncology Treatment Drug Sales Value by Type
  8. 4.2.1 Global Oncology Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oncology Treatment Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global Oncology Treatment Drug Sales Value Share by Type (2021-2032)
5 Oncology Treatment Drug Market by Application
  1. 5.1 Oncology Treatment Drug Application Introduction
  2. 5.1.1 Respiratory/Lung Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Gastrointestinal Cancer
  6. 5.1.5 Blood Cancer
  7. 5.1.6 Others
  8. 5.2 Global Oncology Treatment Drug Sales Value by Application
  9. 5.2.1 Global Oncology Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Oncology Treatment Drug Sales Value by Application (2021-2032)
  11. 5.2.3 Global Oncology Treatment Drug Sales Value Share by Application (2021-2032)
6 Oncology Treatment Drug Regional Value Analysis
  1. 6.1 Global Oncology Treatment Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology Treatment Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oncology Treatment Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oncology Treatment Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncology Treatment Drug Sales Value (2021-2032)
  7. 6.3.2 North America Oncology Treatment Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oncology Treatment Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Oncology Treatment Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oncology Treatment Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oncology Treatment Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oncology Treatment Drug Sales Value (2021-2032)
  16. 6.6.2 South America Oncology Treatment Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oncology Treatment Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oncology Treatment Drug Sales Value Share by Country, 2025 VS 2032
7 Oncology Treatment Drug Country-level Value Analysis
  1. 7.1 Global Oncology Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology Treatment Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oncology Treatment Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oncology Treatment Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oncology Treatment Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oncology Treatment Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oncology Treatment Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Oncology Treatment Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Oncology Treatment Drug Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Oncology Treatment Drug Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Oncology Treatment Drug Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Oncology Treatment Drug Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Oncology Treatment Drug Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Merck KGaA
  38. 8.7.1 Merck KGaA Company Information
  39. 8.7.2 Merck KGaA Business Overview
  40. 8.7.3 Merck KGaA Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck KGaA Oncology Treatment Drug Product Portfolio
  42. 8.7.5 Merck KGaA Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Oncology Treatment Drug Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Oncology Treatment Drug Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Oncology Treatment Drug Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Oncology Treatment Drug Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Oncology Treatment Drug Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Oncology Treatment Drug Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Oncology Treatment Drug Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Otsuka
  86. 8.15.1 Otsuka Company Information
  87. 8.15.2 Otsuka Business Overview
  88. 8.15.3 Otsuka Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Otsuka Oncology Treatment Drug Product Portfolio
  90. 8.15.5 Otsuka Recent Developments
  91. 8.16 Merck & Co.
  92. 8.16.1 Merck & Co. Company Information
  93. 8.16.2 Merck & Co. Business Overview
  94. 8.16.3 Merck & Co. Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck & Co. Oncology Treatment Drug Product Portfolio
  96. 8.16.5 Merck & Co. Recent Developments
  97. 8.17 Ipsen
  98. 8.17.1 Ipsen Company Information
  99. 8.17.2 Ipsen Business Overview
  100. 8.17.3 Ipsen Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ipsen Oncology Treatment Drug Product Portfolio
  102. 8.17.5 Ipsen Recent Developments
  103. 8.18 Gilead Sciences
  104. 8.18.1 Gilead Sciences Company Information
  105. 8.18.2 Gilead Sciences Business Overview
  106. 8.18.3 Gilead Sciences Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gilead Sciences Oncology Treatment Drug Product Portfolio
  108. 8.18.5 Gilead Sciences Recent Developments
  109. 8.19 Celgene
  110. 8.19.1 Celgene Company Information
  111. 8.19.2 Celgene Business Overview
  112. 8.19.3 Celgene Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Celgene Oncology Treatment Drug Product Portfolio
  114. 8.19.5 Celgene Recent Developments
  115. 8.20 Bristol-Myers Squibb
  116. 8.20.1 Bristol-Myers Squibb Company Information
  117. 8.20.2 Bristol-Myers Squibb Business Overview
  118. 8.20.3 Bristol-Myers Squibb Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Bristol-Myers Squibb Oncology Treatment Drug Product Portfolio
  120. 8.20.5 Bristol-Myers Squibb Recent Developments
  121. 8.21 Biogen Idec
  122. 8.21.1 Biogen Idec Company Information
  123. 8.21.2 Biogen Idec Business Overview
  124. 8.21.3 Biogen Idec Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Biogen Idec Oncology Treatment Drug Product Portfolio
  126. 8.21.5 Biogen Idec Recent Developments
  127. 8.22 Astellas
  128. 8.22.1 Astellas Company Information
  129. 8.22.2 Astellas Business Overview
  130. 8.22.3 Astellas Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Astellas Oncology Treatment Drug Product Portfolio
  132. 8.22.5 Astellas Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst